HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guthy-Renker Stands Firm Against NAD Finding On Crepe Erase Wrinkle Claim

Executive Summary

Guthy-Renker disagrees with NAD's position the firm does not have objective evidence to support its treatment can “reverse crepey-looking skin.” NAD attorneys say the nature and extent of claims "should be directly analogous to the precision and specificity of the data used to substantiate.”

You may also be interested in...



National Advertising Review Board Finds For Guthy-Renker In Crepe Erase Case

Can Guthy-Renker’s Crepe Erase system “reverse” crepey-looking skin? The NARB overturns the National Advertising Division’s August decision in the matter, finding the company’s evidence adequate to support that claim and others, in a 17 December ruling.

Health And Wellness Market News: X Out Acne Line In GNC, Eosera In Rite Aid

Proactiv marketer Guthy Renker introduces X Out acne line in GNC stores; Eosera reaches Rite Aid, plans extensions; ANSI meeting discusses supply chain safety, standards; and Dr. Reddy’s launches Mucinex D equivalent.

Exuviance Before/After Photos Overexpose Results – NAD

NeoStrata will modify a print ad for its Exuviance anti-aging skin care products after NAD finds that “before” and “after” photos imply a claim about efficacy not supported by a study for one, though similar images are supported by a study on the efficacy of the second.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149077

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel